Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance

Background Allergen‐specific immunotherapy (SIT) is associated with increased levels of allergen‐specific IgG in serum. However, it is not clear to what extent qualitative changes in the allergen binding capacity of IgG may be induced as well.

[1]  A. Enk,et al.  Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells. , 2001, The Journal of allergy and clinical immunology.

[2]  P. Howarth,et al.  Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. , 1996, Thorax.

[3]  J. Hunyadi,et al.  Increased frequency of intracellular interleukin (IL)‐13 and IL‐10, but not IL‐4, expressing CD4+ and CD8+ peripheral T cells of patients with atopic dermatitis , 2002, The British journal of dermatology.

[4]  A. Michils,et al.  Mite allergy is associated with a specific profile of IgG epitopes recognized on antigen p1 of Dermatophagoides pteronyssinus , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  K. Hoffmann‐Sommergruber,et al.  Isoforms of Bet v 1, the Major Birch Pollen Allergen, Analyzed by Liquid Chromatography, Mass Spectrometry, and cDNA Cloning (*) , 1995, The Journal of Biological Chemistry.

[6]  S. Durham,et al.  Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  P. Roepstorff,et al.  Characterisation of recombinant isoforms of birch pollen allergen Bet v 1. , 1996, Advances in Experimental Medicine and Biology.

[8]  B. Chatterjee,et al.  The immunological and clinical effects of immunotherapy in patients suffering from house dust allergy. , 1999, Annals of agricultural and environmental medicine : AAEM.

[9]  D. Umetsu,et al.  The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. , 1999, The Journal of allergy and clinical immunology.

[10]  S. Durham,et al.  Immunologic changes associated with allergen immunotherapy. , 1998, The Journal of allergy and clinical immunology.

[11]  A. Kay,et al.  Interleukin‐10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy , 2001, European journal of immunology.

[12]  R. de Boer,et al.  In vitro production of IgG4 by peripheral blood mononuclear cells (PBMC): the contribution of committed B cells , 1998, Clinical and experimental immunology.

[13]  T. Haahtela,et al.  Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. , 2001, Annals of Allergy, Asthma & Immunology.

[14]  K. Hoffmann‐Sommergruber,et al.  Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. , 1993, European journal of biochemistry.

[15]  D. Umetsu,et al.  TH1 and TH2 CD4+ cells in human allergic diseases. , 1997, The Journal of allergy and clinical immunology.

[16]  L. Klimek,et al.  Tree‐pollen allergy is efficiently treated by short‐term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens , 1998, Allergy.

[17]  J. Bonnefoy,et al.  IgE versus IgG4 production can be differentially regulated by IL-10. , 1998, Journal of immunology.

[18]  S. Durham,et al.  Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. , 1991, BMJ.

[19]  D. Altschuh,et al.  Measurement of antigen–antibody interactions with biosensors , 1998, Journal of molecular recognition : JMR.

[20]  K. Bendtzen,et al.  Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. , 2003, Molecular immunology.

[21]  S. Durham,et al.  Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[22]  R. Valenta,et al.  Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  Gossart,et al.  Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  M. Loveless.  Immunological Studies of Pollinosis: I. The Presence of Two Antibodies Related to the Same Pollen-Antigen in the Serum of Treated Hay-Fever Patients , 1940 .

[25]  H. Malling,et al.  The safety and efficacy of subcutaneous birch pollen immunotherapy – a one‐year, randomised, double‐blind, placebo‐controlled study , 2002, Allergy. European Journal of Allergy and Clinical Immunology.

[26]  K. Mathews.  Immunotherapy for allergic disease. , 1976, Comprehensive therapy.

[27]  C. Radauer,et al.  New Bet v 1 isoforms including a naturally occurring truncated form of the protein derived from Austrian birch pollen. , 1999, Molecular immunology.

[28]  R. Valenta,et al.  Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. , 1998, The Journal of allergy and clinical immunology.

[29]  H. Løwenstein,et al.  The significance of isoallergenic variations in present and future specific immunotherapy. , 1995, International archives of allergy and immunology.

[30]  M. Gajhede,et al.  Molecular basis of allergic cross-reactivity between group 1 major allergens from birch and apple. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[31]  L. Noon.  Prophylactic inoculation against hay fever. , 1911, International archives of allergy and applied immunology.

[32]  B. García,et al.  Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. , 2002, The Journal of allergy and clinical immunology.

[33]  M. Breitenbach,et al.  IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa* , 1989, Allergy.

[34]  R. Cooke,et al.  SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER) , 1935, The Journal of experimental medicine.

[35]  M. Blumenthal,et al.  Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.